DOCSLIB.ORG

Table S16:Probe Sets with Significant Variation in Human Datasets from the Met1 Versus DB7 Tumor Comparison Probe Set GSE1456 G

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table S16:Probe Sets with Significant Variation in Human Datasets from the Met1 Versus DB7 Tumor Comparison Probe Set GSE1456 G Table S16:Probe sets with significant variation in human datasets from the Met1 versus DB7 tumor comparison Probe set GSE1456 GSE2034 GSE3494 GSE4922 Rosetta Gene Symbol Gene Title 1552619_a_at 0 0 0 0 NM_018685 ANLN anillin, actin binding protein 1554006_a_at 0 0 0 0 NM_004524 LLGL2 lethal giant larvae homolog 2 (Drosophila) 1554462_a_at 0 0 0 0 NM_012328 DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 1554930_a_at 0 0 0 0 NM_004480 FUT8 fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 1555037_a_at 0 0 0 0 NM_005896 IDH1 isocitrate dehydrogenase 1 (NADP+), soluble 1555445_at 0 0 0 0 NM_004056 CA8 carbonic anhydrase VIII 1555540_at 0 0 0 0 NM_003239 TGFB3 transforming growth factor, beta 3 1555551_at 0 0 0 0 NM_002639 SERPINB5 serpin peptidase inhibitor, clade B (ovalbumin), member 5 1555997_s_at 0 0 0 0 AF055033 IGFBP5 insulin-like growth factor binding protein 5 1558393_at 0 0 0 0 NM_005556 KRT7 keratin 7 1558394_s_at 0 0 0 0 NM_005556 KRT7 keratin 7 1561557_at 0 0 0 0 NM_000235 LIPA Lipase A, lysosomal acid, cholesterol esterase (Wolman disease) 1565772_at 0 0 0 0 NM_002576 PAK1 p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) 1568574_x_at 0 0 0 0 NM_000582 SPP1 Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1) 1568618_a_at 0 0 0 0 NM_020474 GALNT1 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1) 1598_g_at 1598_g_at 0 1598_g_at 1598_g_at NM_000820 GAS6 growth arrest-specific 6 200047_s_at 200047_s_at 0 200047_s_at200047_s_at 0 YY1 YY1 transcription factor 200607_s_at 200607_s_at200607_s_at200607_s_at200607_s_atContig59951 RAD21 RAD21 homolog (S. pombe) 200608_s_at 200608_s_at 0 200608_s_at200608_s_atContig59951 RAD21 RAD21 homolog (S. pombe) 200622_x_at 200622_x_at 0 200622_x_at200622_x_at 0 CALM3 calmodulin 3 (phosphorylase kinase, delta) 200623_s_at 200623_s_at 0 0 0 0 CALM3 calmodulin 3 (phosphorylase kinase, delta) 200654_at 200654_at 0 200654_at 200654_at 0 P4HB procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide 200656_s_at 200656_s_at200656_s_at200656_s_at200656_s_at 0 P4HB procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide 200704_at 200704_at 0 200704_at 200704_at 0 LITAF lipopolysaccharide-induced TNF factor 200706_s_at 200706_s_at 0 200706_s_at200706_s_at 0 LITAF lipopolysaccharide-induced TNF factor 200795_at 200795_at 200795_at 200795_at 200795_at NM_004684 SPARCL1 SPARC-like 1 (mast9, hevin) 200799_at 200799_at 0 200799_at 200799_at NM_005345 HSPA1A heat shock 70kDa protein 1A 200800_s_at 200800_s_at 0 200800_s_at200800_s_at 0 HSPA1A /// HSPA1B heat shock 70kDa protein 1A /// heat shock 70kDa protein 1B 200853_at 200853_at 0 200853_at 200853_at NM_002106 H2AFZ H2A histone family, member Z 200929_at 200929_at 0 200929_at 200929_at 0 TMED10 transmembrane emp24-like trafficking protein 10 (yeast) 200969_at 200969_at 0 200969_at 200969_at 0 SERP1 stress-associated endoplasmic reticulum protein 1 200970_s_at 200970_s_at 0 200970_s_at200970_s_at 0 SERP1 stress-associated endoplasmic reticulum protein 1 200971_s_at 200971_s_at 0 200971_s_at200971_s_at 0 SERP1 stress-associated endoplasmic reticulum protein 1 201118_at 201118_at 201118_at 201118_at 201118_at 0 PGD phosphogluconate dehydrogenase 201145_at 201145_at 0 0 0 0 HAX1 HCLS1 associated protein X-1 201167_x_at 201167_x_at201167_x_at201167_x_at201167_x_at 0 ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha 201168_x_at 201168_x_at 0 0 0 0 ARHGDIA /// LOC728908 Rho GDP dissociation inhibitor (GDI) alpha /// similar to Rho GDP dissociation inhibitor (GDI) alpha 201192_s_at 201192_s_at 0 201192_s_at201192_s_at 0 PITPNA phosphatidylinositol transfer protein, alpha 201193_at 201193_at 0 201193_at 201193_at NM_005896 IDH1 isocitrate dehydrogenase 1 (NADP+), soluble 201215_at 201215_at 0 201215_at 201215_at NM_005032 PLS3 plastin 3 (T isoform) 201242_s_at 201242_s_at201242_s_at201242_s_at201242_s_atNM_001677 ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 201243_s_at 201243_s_at201243_s_at201243_s_at201243_s_atNM_001677 ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 201291_s_at 201291_s_at201291_s_at201291_s_at201291_s_atNM_001067 TOP2A topoisomerase (DNA) II alpha 170kDa 201292_at 201292_at 201292_at 201292_at 201292_at NM_001067 TOP2A topoisomerase (DNA) II alpha 170kDa 201303_at 201303_at 0 201303_at 201303_at 0 EIF4A3 eukaryotic translation initiation factor 4A, isoform 3 201339_s_at 201339_s_at 0 201339_s_at201339_s_atNM_002979 SCP2 sterol carrier protein 2 201349_at 201349_at 201349_at 201349_at 201349_at NM_004252 SLC9A3R1 solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1 201367_s_at 201367_s_at201367_s_at201367_s_at201367_s_at 0 ZFP36L2 zinc finger protein 36, C3H type-like 2 201368_at 201368_at 0 201368_at 201368_at 0 ZFP36L2 zinc finger protein 36, C3H type-like 2 201369_s_at 201369_s_at201369_s_at201369_s_at201369_s_at 0 ZFP36L2 zinc finger protein 36, C3H type-like 2 201470_at 201470_at 0 201470_at 201470_at 0 GSTO1 glutathione S-transferase omega 1 201476_s_at 201476_s_at 0 201476_s_at201476_s_at 0 RRM1 ribonucleotide reductase M1 polypeptide 201477_s_at 201477_s_at 0 201477_s_at201477_s_at 0 RRM1 ribonucleotide reductase M1 polypeptide 201559_s_at 201559_s_at 0 201559_s_at201559_s_at 0 CLIC4 chloride intracellular channel 4 201560_at 201560_at 0 201560_at 201560_at 0 CLIC4 chloride intracellular channel 4 201596_x_at 201596_x_at201596_x_at201596_x_at201596_x_atNM_000224 KRT18 keratin 18 201599_at 201599_at 0 201599_at 201599_at NM_000274 OAT ornithine aminotransferase (gyrate atrophy) 201663_s_at 201663_s_at 0 201663_s_at201663_s_at 0 SMC4 structural maintenance of chromosomes 4 201664_at 201664_at 0 201664_at 201664_at 0 SMC4 structural maintenance of chromosomes 4 201722_s_at 201722_s_at 0 201722_s_at201722_s_atNM_020474 GALNT1 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1) 201723_s_at 201723_s_at 0 201723_s_at201723_s_atNM_020474 GALNT1 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1) 201724_s_at 201724_s_at 0 201724_s_at201724_s_atNM_020474 GALNT1 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1) 201755_at 201755_at 201755_at 201755_at 201755_at NM_006739 MCM5 minichromosome maintenance complex component 5 201761_at 201761_at 0 201761_at 201761_at NM_006636 MTHFD2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase 201795_at 201795_at 201795_at 201795_at 201795_at NM_002296 LBR lamin B receptor 201801_s_at 201801_s_at201801_s_at201801_s_at201801_s_atNM_004955 SLC29A1 solute carrier family 29 (nucleoside transporters), member 1 201802_at 201802_at 0 201802_at 201802_at NM_004955 SLC29A1 solute carrier family 29 (nucleoside transporters), member 1 201810_s_at 201810_s_at 0 201810_s_at201810_s_atNM_004844 SH3BP5 SH3-domain binding protein 5 (BTK-associated) 201811_x_at 201811_x_at 0 201811_x_at201811_x_atNM_004844 SH3BP5 SH3-domain binding protein 5 (BTK-associated) 201829_at 201829_at 0 201829_at 201829_at NM_005863 NET1 neuroepithelial cell transforming gene 1 201830_s_at 201830_s_at201830_s_at201830_s_at201830_s_atNM_005863 NET1 neuroepithelial cell transforming gene 1 201841_s_at 201841_s_at201841_s_at201841_s_at201841_s_atNM_001540 HSPB1 heat shock 27kDa protein 1 201847_at 201847_at 0 201847_at 201847_at NM_000235 LIPA lipase A, lysosomal acid, cholesterol esterase (Wolman disease) 201889_at 201889_at 0 201889_at 201889_at 0 FAM3C family with sequence similarity 3, member C 201901_s_at 201901_s_at 0 201901_s_at201901_s_at 0 YY1 YY1 transcription factor 201902_s_at 0 201902_s_at 0 0 0 YY1 YY1 transcription factor 201925_s_at 201925_s_at 0 201925_s_at201925_s_at 0 CD55 CD55 molecule, decay accelerating factor for complement (Cromer blood group) 201926_s_at 201926_s_at 0 201926_s_at201926_s_at 0 CD55 CD55 molecule, decay accelerating factor for complement (Cromer blood group) 201930_at 201930_at 0 201930_at 201930_at NM_005915 MCM6 minichromosome maintenance complex component 6 201983_s_at 201983_s_at201983_s_at201983_s_at201983_s_at 0 EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) 201984_s_at 201984_s_at201984_s_at201984_s_at201984_s_at 0 EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) 202018_s_at 202018_s_at202018_s_at202018_s_at202018_s_at 0 LOC728320 /// LTF lactotransferrin /// similar to lactotransferrin 202022_at 202022_at 0 202022_at 202022_at NM_005165 ALDOC aldolase C, fructose-bisphosphate 202069_s_at 202069_s_at 0 202069_s_at202069_s_at 0 IDH3A isocitrate dehydrogenase 3 (NAD+) alpha 202070_s_at 0 0 202070_s_at202070_s_at 0 IDH3A isocitrate dehydrogenase 3 (NAD+) alpha 202082_s_at 202082_s_at 0 202082_s_at202082_s_at 0 SEC14L1 SEC14-like 1 (S. cerevisiae) 202083_s_at 202083_s_at202083_s_at202083_s_at202083_s_at 0 SEC14L1 SEC14-like 1 (S. cerevisiae) 202084_s_at 202084_s_at 0 202084_s_at202084_s_at 0 SEC14L1 SEC14-like 1 (S.
Load more

Recommended publications
  • Meta-Analysis and Inding from Seoul Breast Cancer Study (SEBCS)
    The Pharmacogenomics Journal https://doi.org/10.1038/s41397-018-0016-6 ARTICLE Associations between genetic polymorphisms of membrane transporter genes and prognosis after chemotherapy: meta-analysis and finding from Seoul Breast Cancer Study (SEBCS) 1 1 1 1 2 3 4 Ji-Eun Kim ● Jaesung Choi ● JooYong Park ● Chulbum Park ● Se Mi Lee ● Seong Eun Park ● Nan Song ● 5 6 4,7 8 1,4,9 10 Seokang Chung ● Hyuna Sung ● Wonshik Han ● Jong Won Lee ● Sue K. Park ● Mi Kyung Kim ● 4,7 9,11 1,4,9,12 1,4,9 Dong-Young Noh ● Keun-Young Yoo ● Daehee Kang ● Ji-Yeob Choi Received: 7 June 2017 / Revised: 13 October 2017 / Accepted: 4 December 2017 © Macmillan Publishers Limited, part of Springer Nature 2018 Abstract Membrane transporters can be major determinants of the pharmacokinetic profiles of anticancer drugs. The associations between genetic variations of ATP-binding cassette (ABC) and solute carrier (SLC) genes and cancer survival were investigated through a meta-analysis and an association study in the Seoul Breast Cancer Study (SEBCS). Including the SEBCS, the meta-analysis was conducted among 38 studies of genetic variations of transporters on various cancer survivors. 1234567890();,: The population of SEBCS consisted of 1 338 breast cancer patients who had been treated with adjuvant chemotherapy. A total of 7 750 SNPs were selected from 453 ABC and/or SLC genes typed by an Affymetrix 6.0 chip. ABCB1 rs1045642 was associated with poor progression-free survival in a meta-analysis (HR = 1.33, 95% CI: 1.07–1.64). ABCB1, SLC8A1, and SLC12A8 were associated with breast cancer survival in SEBCS (Pgene < 0.05).
    [Show full text]
  • New Products JULY 2013
    R&D Systems Tools for Cell Biology Research™ New Products JULY 2013 GMP-grade Recombinant Proteins Contents R&D Systems now offers GMP-grade cytokines and growth factors for research and further manu- facturing applications where current Good Manufacturing Practices (GMP) are required. GMP-grade Recombinant Proteins 2 proteins are manufactured in our ISO-certified facility in compliance with relevant guidelines1 and are produced with extensive documentation at every stage of development from cell culture to final fill and Quantikine® ELISA Kits 3 formulation. GMP-grade Recombinant Human IL-6 and Recombinant Human TNF-a have recently been added to our line of GMP-grade proteins. Additional GMP-grade proteins will be available in the next several months. For an up-to-date product listing or additional information, please visit our website at Luminex® Screening Assays 4 www.RnDSystems.com/GMP. Luminex® Performance Assays 4-5 Features New GMP Proteins ✓ Extensive documentation at every stage of development ProtEin SOURCE Catalog # SIZE Polyclonal Antibodies 6-7 ✓ Documentation of lot-to-lot consistency and traceability Human IL-6 E. coli 206-GMP-010 10 µg Monoclonal Antibodies 7-8 of materials used 206-GMP-050 50 µg ✓ Rigorous quality control using stringent analytical 206-GMP-01M 1 mg processes Biotinylated Antibodies 8 Human TNF-a/ E. coli 210-GMP-010 10 µg ✓ Proven formulations to ensure consistent reconstitution TNFSF1A and results 210-GMP-050 50 µg Antibody Controls 8 210-GMP-01M 1 mg ELISpot Kits & Development Modules 8 30000 60 Fluorokine® Flow Cytometry Kits 8 25000 17348 ) 2 50 20000 Fluorochrome-labeled Antibodies 9 40 8673 DuoSet® ELISA and DuoSet IC ELISA 15000 Development Systems 10 30 Peak Intensity Peak 10000 20 Cell-Based ELISA Assay Kits 10 5000 17565 (Mean RFU x10 Viability Cell 8780 10 Parameter Assay Kits 10 0 0 6000 9000 12000 15000 18000 21000 24000 -3 -2 -1 0 1 10 10 10 10 10 Apoptosis Detection 10 Mass Charge Ratio Recombinant Human TNF-α GMP (ng/mL) MALDI-TOF Analysis of GMP-grade Recombinant Human TNF-a.
    [Show full text]
  • Supplementary Table 1. All Differentially Expressed Genes from Microarray Screening Analysis
    Supplementary Table 1. All differentially expressed genes from microarray screening analysis. FCa (Gal-KD Gene Symbol Gene Name p-Value versus Vector) Up-regulated genes HAPLN1 hyaluronan and proteoglycan link protein 1 10.49 0.0027085 THBS1 thrombospondin 1 9.20 0.0022192 ODC1 ornithine decarboxylase 1 6.38 0.0055776 TGM2 transglutaminase 2 4.76 0.0015627 IL7R interleukin 7 receptor 4.75 0.0017245 SERINC2 serine incorporator 2 4.51 0.0014919 ITM2C integral membrane protein 2C 4.32 0.0044644 SERPINB7 serpin peptidase inhibitor, clade B, member 7 4.18 0.0081136 tumor necrosis factor receptor superfamily, member TNFRSF10D 4.01 0.0085561 10d TAGLN transgelin 3.90 0.0099963 LRRN4 leucine rich repeat neuronal 4 3.82 0.0046513 TGFB2 transforming growth factor beta 2 3.51 0.0035017 CPA4 carboxypeptidase A4 3.43 0.0008452 EPB41L3 erythrocyte membrane protein band 4.1-like 3 3.34 0.0025309 NRG1 neuregulin 1 3.28 0.0079724 F3 coagulation factor III (thromboplastin, tissue factor) 3.27 0.0038968 POLR3G polymerase III polypeptide G 3.26 0.0070675 SEMA7A semaphorin 7A 3.20 0.0087335 NT5E 5-nucleotidase 3.17 0.0036353 CAMK2N1 calmodulin-dependent protein kinase II inhibitor 1 3.07 0.0090141 TIMP3 TIMP metallopeptidase inhibitor 3 3.03 0.0047953 SERPINE1 serpin peptidase inhibitor, clade E 2.97 0.0053652 MALL mal, T-cell differentiation protein-like 2.88 0.0078205 DDAH1 dimethylarginine dimethylaminohydrolase 1 2.86 0.0002895 WDR3 WD repeat domain 3 2.85 0.0058842 WNT5A Wnt Family Member 5A 2.81 0.0043796 GPR1 G protein-coupled receptor 1 2.81 0.0021313
    [Show full text]
  • Supplementary Material Contents
    Supplementary Material Contents Immune modulating proteins identified from exosomal samples.....................................................................2 Figure S1: Overlap between exosomal and soluble proteomes.................................................................................... 4 Bacterial strains:..............................................................................................................................................4 Figure S2: Variability between subjects of effects of exosomes on BL21-lux growth.................................................... 5 Figure S3: Early effects of exosomes on growth of BL21 E. coli .................................................................................... 5 Figure S4: Exosomal Lysis............................................................................................................................................ 6 Figure S5: Effect of pH on exosomal action.................................................................................................................. 7 Figure S6: Effect of exosomes on growth of UPEC (pH = 6.5) suspended in exosome-depleted urine supernatant ....... 8 Effective exosomal concentration....................................................................................................................8 Figure S7: Sample constitution for luminometry experiments..................................................................................... 8 Figure S8: Determining effective concentration .........................................................................................................
    [Show full text]
  • Supplemental Data 5-21-18
    Supplemental Methods and Data Androgen receptor polyglutamine expansion drives age-dependent quality control defects and muscle dysfunction Samir R. Nath1,2,3, Zhigang Yu1, Theresa A. Gipson4, Gregory B. Marsh5, Eriko Yoshidome1, Diane M. Robins6, Sokol V. Todi5, David E. Housman4, Andrew P. Lieberman1 1 Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109 2 Medical Scientist Training Program, University of Michigan Medical School, Ann Arbor, MI 48109 3 Cellular and Molecular Biology Graduate Program, University of Michigan Medical School, Ann Arbor, MI 48109 4 Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139 5 Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201 6 Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI 48109 Supplemental Methods qPCR For Drosophila samples, total RNA was extracted from adult fly heads using TRIzol. Fifteen heads were used per sample. Extracted RNA was treated with TURBO DNAse (Ambion) to eliminate contaminating DNA, and reverse transcription was carried out as indicated above. RNA levels were quantified using StepOnePlus Real-Time PCR System with Fast SYBR Green Master Mix (Applied Biosystems). rp49 was used as the internal control. Each round of qRT-PCR was conducted in technical triplicates. A total of three independent repeats was conducted. Fly histology: For histological preparation (75, 76), wings and proboscises of adult flies were removed and bodies were fixed overnight in 2% glutaraldehyde/2% paraformaldehyde in Tris- buffered saline with 0.1% Triton X-100, rotating at 4˚C. Fixed bodies were subsequently dehydrated by using a series of 30%, 50%, 75%, and 100% ethanol/propylene oxide.
    [Show full text]
  • Supporting Information
    Supporting Information Table S1. List of confirmed SLC transporters represented in Canine GeneChip. SLC family Members detected Members not detected SLC1: The high affinity glutamate and neutral amino acid SLC1A1 SLC1A2, SLC1A3, SLC1A6 transporter family SLC2: The facilitative GLUT transporter family SLC2A1, SLC2A8 SLC2A3, SLC2A9 SLC3: The heavy subunits of the heteromeric amino acid SLC3A1 transporters SLC4: The bicarbonate transporter family SLC4A11 SLC4A4, SLC4A8 SLC5: The sodium glucose cotransporter family SLC5A6 SLC5A3, SLC5A10, SLC5A12 SLC6: The sodium- and chloride- dependent SLC6A6, SLC6A12 SLCA18 neurotransmitter transporter family SLC7: The cationic amino acid transporter/glycoprotein- NR associated family SLC8: The Na+/Ca2+ exchanger family SLC8A1 SLC9: The Na+/H+ exchanger family SLC9A1, SLC9A6, SLC9A9 SLC10: The sodium bile salt cotransport family SLC10A2 SLC11: The proton coupled metal ion transporter family NR SLC12: The electroneutral cation-Cl cotransporter family SLC12A3, SLC12A6, SLC12A8 SLC13: The human Na+-sulfate/carboxylate cotransporter SLC13A2 family SLC14: The urea transporter family NR SLC15: The proton oligopeptide cotransporter family SLC15A2, SLC15A4 SLC15A1 SLC16: The monocarboxylate transporter family SLC16A13 SLC16A4 SLC17: The vesicular glutamate transporter family SLC17A3, SLC17A7 SLC18: The vesicular amine transporter family NR SLC19: The folate/thiamine transporter family NR SLC20: The type III Na+-phosphate cotransporter family NR SLC21/SLCO: The organic anion transporting family SLC21A3, SLC21A8,
    [Show full text]
  • Activation of RAS Signalling Is Associated with Altered Cell Adhesion in Phaeochromocytoma” by Hugo M
    Supplementary Information for “Activation of RAS Signalling is Associated with Altered Cell Adhesion in Phaeochromocytoma” by Hugo M. Rossitti, Ravi Kumar Dutta, Catharina Larsson, Hans K. Ghayee, Peter Söderkvist, and Oliver Gimm. Supplementary Figures Supplementary Figure S1: Confirmation of KIF1B T827I mutation in hPheo1 cell line through Sanger sequencing. KIF1B cDNA sequence trace corresponding to codons 824-830 from hPheo1 cells with forward (coding sequence, A) and reverse primers (complement, B). 1 Supplementary Figure S2: Confirmation of NRAS Q61K mutation in hPheo1 cell line through Sanger sequencing. NRAS cDNA sequence trace corresponding to codons 56-67 from hPheo1 cells with forward (coding sequence, A) and reverse primers (complement, B). 2 Supplementary Figure S3: CCND1 gene expression and hPheo1 proliferation. A: Expression of CCND1 mRNA assessed by RT-qPCR and presented as fold change (2-ΔΔCT, mean ± standard error of the mean). B: Cell counts at 1, 2, and 3 days after plating (corresponding to 72, 96 and 120 hours posttransfection, respectively) of control- or siNRAS#1-transfected hPheo1 cells expressed as fold change of the number of cells plated at day 0 (48 hours posttransfection; mean ± standard deviation). All results are from three independent siRNA experiments. 3 Supplementary Tables Supplementary Table S1: List of transcript cluster IDs significantly upregulated in hPheo1 by siNRAS treatment (comparison: siNRAS versus control-transfected hPheo1; ANOVA p < 0.05, FDR < 0.25, fold change < -1.5 or > 1.5). Transcript
    [Show full text]
  • Identification of Placental Nutrient Transporters Associated With
    Huang et al. BMC Genomics (2018) 19:173 https://doi.org/10.1186/s12864-018-4518-z RESEARCHARTICLE Open Access Identification of placental nutrient transporters associated with intrauterine growth restriction and pre-eclampsia Xiao Huang1,2, Pascale Anderle3,4, Lu Hostettler2, Marc U. Baumann1,5, Daniel V. Surbek1,5, Edgar C. Ontsouka1,2 and Christiane Albrecht1,2* Abstract Background: Gestational disorders such as intrauterine growth restriction (IUGR) and pre-eclampsia (PE) are main causes of poor perinatal outcomes worldwide. Both diseases are related with impaired materno-fetal nutrient transfer, but the crucial transport mechanisms underlying IUGR and PE are not fully elucidated. In this study, we aimed to identify membrane transporters highly associated with transplacental nutrient deficiencies in IUGR/PE. Results: In silico analyses on the identification of differentially expressed nutrient transporters were conducted using seven eligible microarray datasets (from Gene Expression Omnibus), encompassing control and IUGR/PE placental samples. Thereby 46 out of 434 genes were identified as potentially interesting targets. They are involved in the fetal provision with amino acids, carbohydrates, lipids, vitamins and microelements. Targets of interest were clustered into a substrate-specific interaction network by using Search Tool for the Retrieval of Interacting Genes. The subsequent wet-lab validation was performed using quantitative RT-PCR on placentas from clinically well- characterized IUGR/PE patients (IUGR, n =8;PE,n =5;PE+IUGR,n = 10) and controls (term, n = 13; preterm, n = 7), followed by 2D-hierarchical heatmap generation. Statistical evaluation using Kruskal-Wallis tests was then applied to detect significantly different expression patterns, while scatter plot analysis indicated which transporters were predominantly influenced by IUGR or PE, or equally affected by both diseases.
    [Show full text]
  • RNA-Seq Reveals Conservation of Function Among the Yolk Sacs Of
    RNA-seq reveals conservation of function among the PNAS PLUS yolk sacs of human, mouse, and chicken Tereza Cindrova-Daviesa, Eric Jauniauxb, Michael G. Elliota,c, Sungsam Gongd,e, Graham J. Burtona,1, and D. Stephen Charnock-Jonesa,d,e,1,2 aCentre for Trophoblast Research, Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, CB2 3EG, United Kingdom; bElizabeth Garret Anderson Institute for Women’s Health, Faculty of Population Health Sciences, University College London, London, WC1E 6BT, United Kingdom; cSt. John’s College, University of Cambridge, Cambridge, CB2 1TP, United Kingdom; dDepartment of Obstetrics and Gynaecology, University of Cambridge, Cambridge, CB2 0SW, United Kingdom; and eNational Institute for Health Research, Cambridge Comprehensive Biomedical Research Centre, Cambridge, CB2 0QQ, United Kingdom Edited by R. Michael Roberts, University of Missouri-Columbia, Columbia, MO, and approved May 5, 2017 (received for review February 14, 2017) The yolk sac is phylogenetically the oldest of the extraembryonic yolk sac plays a critical role during organogenesis (3–5, 8–10), membranes. The human embryo retains a yolk sac, which goes there are limited data to support this claim. Obtaining experi- through primary and secondary phases of development, but its mental data for the human is impossible for ethical reasons, and importance is controversial. Although it is known to synthesize thus we adopted an alternative strategy. Here, we report RNA proteins, its transport functions are widely considered vestigial. sequencing (RNA-seq) data derived from human and murine yolk Here, we report RNA-sequencing (RNA-seq) data for the human sacs and compare them with published data from the yolk sac of and murine yolk sacs and compare those data with data for the the chicken.
    [Show full text]
  • Lineage-Specific Effector Signatures of Invariant NKT Cells Are Shared Amongst Δγ T, Innate Lymphoid, and Th Cells
    Downloaded from http://www.jimmunol.org/ by guest on September 26, 2021 δγ is online at: average * The Journal of Immunology , 10 of which you can access for free at: 2016; 197:1460-1470; Prepublished online 6 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600643 http://www.jimmunol.org/content/197/4/1460 Lineage-Specific Effector Signatures of Invariant NKT Cells Are Shared amongst T, Innate Lymphoid, and Th Cells You Jeong Lee, Gabriel J. Starrett, Seungeun Thera Lee, Rendong Yang, Christine M. Henzler, Stephen C. Jameson and Kristin A. Hogquist J Immunol cites 41 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription http://www.jimmunol.org/content/suppl/2016/07/06/jimmunol.160064 3.DCSupplemental This article http://www.jimmunol.org/content/197/4/1460.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 26, 2021. The Journal of Immunology Lineage-Specific Effector Signatures of Invariant NKT Cells Are Shared amongst gd T, Innate Lymphoid, and Th Cells You Jeong Lee,* Gabriel J.
    [Show full text]
  • Transporters
    University of Dundee The Concise Guide to PHARMACOLOGY 2015/16 Alexander, Stephen P. H.; Kelly, Eamonn; Marrion, Neil; Peters, John A.; Benson, Helen E.; Faccenda, Elena Published in: British Journal of Pharmacology DOI: 10.1111/bph.13355 Publication date: 2015 Licence: CC BY Document Version Publisher's PDF, also known as Version of record Link to publication in Discovery Research Portal Citation for published version (APA): Alexander, S. P. H., Kelly, E., Marrion, N., Peters, J. A., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators (2015). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. British Journal of Pharmacology, 172(24), 6110-6202. https://doi.org/10.1111/bph.13355 General rights Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain. • You may freely distribute the URL identifying the publication in the public portal. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 06. Oct. 2021 S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Transporters.
    [Show full text]
  • Wo 2008/156655 A9
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 24 December 2008 (24.12.2008) PCT WO 2008/156655 A9 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 14/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, (21) International Application Number: CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, PCT/US2008/007377 EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, (22) International Filing Date: 13 June 2008 (13.06.2008) LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, (25) Filing Language: English PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW (30) Priority Data: (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, 60/934,768 15 June 2007 (15.06.2007) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), (71) Applicants (for all designated States except US): European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, GENELUX CORPORATION [US/US]; 3030 Bunker FR, GB, GR, HR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, Hill Street, Suite 310, San Diego, CA 92109 (US).
    [Show full text]